Malarial Drug Delivery Systems

The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause of significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future, primarily due to increased longevity that almost always comes at the cost of impaired immunity.

A total of four books are covered under the series of Infectious drug diseases.

- Malarial drug delivery systems

- Tubercular drug delivery systems

- Viral drug delivery systems

- Infectious disease drug delivery systems

The theme of the first book is Malaria. This book compiles the complete road map of malarial drug delivery systems by understanding the pathophysiology of the disease, the current state of malaria across the globe, new clinical trials, emerging drugs, and the development of novel drug delivery platforms. Various novel micro-and nano-formulations using promising technologies are being explored to deliver the malarial drug via different administration routes. This book addresses the gap between new approaches and old treatment modalities and how the former is superior in pharmacological performance when tested in in-vitro and in-vivo.

Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of malarial research.